Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...
The FDA has approved Janssen’s antidepressant ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...
Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...
Trump’s “first buddy” Elon Musk made a lively, chaotic and unpredictable appearance at the Conservative Political Action ...
China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing postpartum depression (PPD) among women undergoing cesarean delivery. The ...
An unvaccinated child has died from measles in an outbreak in Texas that has grown to include more than 120 cases spanning nine counties, state health officials announced Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results